Deferoxamine to Prevent Delayed Cerebral Ischemia After Subarachnoid Hemorrhage
Deferoxamine: An Emerging Therapy to Prevent Delayed Cerebral Ischemia After Subarachnoid Hemorrhage
Sponsor: Brigham and Women's Hospital
Terminated
Principle Investigator is moving to another institution and plans to restart this proctocol in the new location.
Other terminated trials from Brigham and Women's Hospital
Other Subarachnoid Hemorrhage trials with similar outcome
Listed as NCT02216513, this EARLY_PHASE1 trial focuses on Subarachnoid Hemorrhage and remains terminated or withdrawn. Sponsored by Brigham and Women's Hospital, it has been updated 10 times since 2014, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Terminated EARLY_PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated EARLY_PHASE1
-
Dec 2021 — Jul 2024 [monthly]
Terminated EARLY_PHASE1
-
Jan 2021 — Dec 2021 [monthly]
Terminated EARLY_PHASE1
-
Nov 2020 — Jan 2021 [monthly]
Terminated EARLY_PHASE1
▶ Show 5 earlier versions
-
Jun 2018 — Nov 2020 [monthly]
Terminated EARLY_PHASE1
-
May 2018 — Jun 2018 [monthly]
Terminated EARLY_PHASE1
-
Aug 2017 — May 2018 [monthly]
Terminated EARLY_PHASE1
-
Feb 2017 — Aug 2017 [monthly]
Terminated EARLY_PHASE1
Phase: Phase 0 → EARLY_PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Terminated Phase 0
First recorded
Sep 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Brigham and Women's Hospital
- Dr. Jeffrey Thomas Stroke Shield Foundation
For direct contact, visit the study record on ClinicalTrials.gov .